Zunsemetinib（Cat No.:I044387）is a selective MAPK-activated protein kinase 2 (MK2) inhibitor, developed to modulate inflammatory signaling pathways involved in chronic inflammatory and autoimmune diseases. By targeting MK2, Zunsemetinib disrupts the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β without directly suppressing upstream kinases, allowing for more precise immune modulation. It shows promise in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. With favorable pharmacokinetics and a strong safety profile, Zunsemetinib represents a novel therapeutic strategy aimed at reducing inflammation while preserving essential immune functions.